Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MacroGenics, Inc.
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Raven Biotechnologies